{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:09:51Z","timestamp":1793761791607,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Molteni Farmaceutici"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40360-016-0058-9","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T04:38:19Z","timestamp":1458794299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The opiate dosage adequacy scale for identification of the right methadone dose\u2014a prospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Stephan","family":"Walcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schlote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Verthein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,7]]},"reference":[{"key":"58_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","volume":"106","author":"L Degenhardt","year":"2011","unstructured":"Degenhardt L, Bucelllo C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106:32\u201351.","journal-title":"Addiction"},{"key":"58_CR2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1360-0443.2011.03463.x","volume":"106","author":"J Reimer","year":"2011","unstructured":"Reimer J, Verthein U, Karow A, Sch\u00e4fer I, Naber D, Haasen C. Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance trial. Addiction. 2011;106:1647\u201355.","journal-title":"Addiction"},{"key":"58_CR3","first-page":"243","volume":"52","author":"U Verthein","year":"2013","unstructured":"Verthein U, Sch\u00e4fer I, Degkwitz P. Social integration after 4\u00a0years of heroin assisted treatment [article in German]. Rehabilitation. 2013;52:243\u201350.","journal-title":"Rehabilitation"},{"key":"58_CR4","doi-asserted-by":"crossref","unstructured":"Farrell M, Ward J, Mattick R, Hal W, Stimson GV, des Jarlais D, Gossop M, Strang J. Methadone maintenance treatment in opiate dependence: a review. Br Med J. 1994;309:997\u20131001.","DOI":"10.1136\/bmj.309.6960.997"},{"key":"58_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1360-0443.2007.02090.x","volume":"103","author":"A Gibson","year":"2008","unstructured":"Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O\u2019Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103:462\u20138.","journal-title":"Addiction"},{"key":"58_CR6","doi-asserted-by":"crossref","unstructured":"Soyka M, Tr\u00e4der A, Klotsche J, Haberth\u00fcr A, B\u00fchringer G, Rehm J, Wittchen HU. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. J Forensic Sci. 2012;57:1524\u201330.","DOI":"10.1111\/j.1556-4029.2012.02234.x"},{"key":"58_CR7","volume":"3","author":"F Faggiano","year":"2003","unstructured":"Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003;3, CD002208.","journal-title":"Cochrane Database Syst Rev"},{"key":"58_CR8","volume":"2","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2, CD002207.","journal-title":"Cochrane Database Syst Rev"},{"key":"58_CR9","doi-asserted-by":"crossref","unstructured":"Roux P, Lions C, Michel L, Cohen J, Mora M, Marcellin F, Spire B, Morel A, Carrier MP Karila L, the ANRS Methaville study group. Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians. Curr Pharm Des. 2014;20:4097\u2013105.","DOI":"10.2174\/13816128113199990623"},{"key":"58_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JCP.0b013e3181c8b439","volume":"30","author":"J Trujols","year":"2010","unstructured":"Trujols J, Sinol N, P\u00e9rez de los Cobos J. The need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment. J Clin Psychopharmacol. 2010;30:95\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"58_CR11","first-page":"41","volume":"6","author":"F Gonz\u00e1lez-Saiz","year":"2004","unstructured":"Gonz\u00e1lez-Saiz F. Opiate dosage adequacy scale (O.D.A.S): a clinical diagnostic tool as a guide to dosing decisions. Heroin Addict Rel Clin Probl. 2004;6:41\u201350.","journal-title":"Heroin Addict Rel Clin Probl"},{"key":"58_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1255528","volume":"11","author":"A Gardini","year":"2010","unstructured":"Gardini A, Poehlke T, Reimer J, Walcher S, Weber B. Cultural and linguistic validation of the questionnaire ODAS (EADO) used to determine the adequacy of the daily of methadone as part of a maintenance programme for the treatment of opiate dependence [article in German]. Suchttherapie. 2010;11:138\u201345.","journal-title":"Suchttherapie"},{"key":"58_CR13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/070674370605101003","volume":"51","author":"C Haasen","year":"2006","unstructured":"Haasen C, van den Brink W. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51:635\u201346.","journal-title":"Can J Psychiatry"},{"key":"58_CR14","first-page":"A511","volume":"107","author":"Federal Physician Chamber","year":"2010","unstructured":"Federal Physician Chamber. Directives of the Federal Physician Chamber for substitution treatment of opioid dependent patients [article in German]. Dtsch \u00c4rztebl. 2010;107:A511\u2013516.","journal-title":"Dtsch \u00c4rztebl"},{"key":"58_CR15","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO; 2009."},{"key":"58_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/10826084.2011.620052","volume":"47","author":"S Trautmann","year":"2012","unstructured":"Trautmann S, Wittchen HU. Abstinence orientation and treatment practice: an analysis of German settings providing opioid maintenance therapy. Subst Use Misuse. 2012;47:22\u201330.","journal-title":"Subst Use Misuse"},{"key":"58_CR17","volume-title":"Predictors, moderators and outcomes of substitution treatment (PREMOS)","author":"HU Wittchen","year":"2012","unstructured":"Wittchen HU, B\u00fchringer G, Rehm J. Predictors, moderators and outcomes of substitution treatment (PREMOS). Berlin: German Drug Commissioner; 2012."},{"key":"58_CR18","doi-asserted-by":"crossref","unstructured":"Reimer J, Boniakowski E, Bachner C, Weber B, Tietje W, Verthein U, Walcher S. When higher doses in opioid replacement treatment are still inadequate-association to multidimensional illness severity: a cohort study. Subst Abuse Treat Prev Policy. 2014;9:13.","DOI":"10.1186\/1747-597X-9-13"},{"key":"58_CR19","unstructured":"Gsellhofer B, K\u00fcfner H, Vogt M, Weilder D. European Addiction Severity Index EuropASI. Manual for training and application. Hohengehren: Schneider publishers; 1999."},{"key":"58_CR20","doi-asserted-by":"crossref","unstructured":"Scheurich A, M\u00fcller MJ, Wetzel H, Anghelescu I, Klawe C, Ruppe A, L\u00f6rch B, Himmerich H, Heidenreich M, Schmid G, Hautzinger M, Szegedi A. Reliability and validity of the German version of the European Addiction Severity Index (EuropASI). J Stud Alcohol Drugs. 2000;61:916\u20139.","DOI":"10.15288\/jsa.2000.61.916"},{"key":"58_CR21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00926239708403933","volume":"23","author":"LR Derogatis","year":"1997","unstructured":"Derogatis LR. The Derogatis interview for sexual functioning (DISF\/DISF-SR): an introductory report. J Sex Marital Ther. 1997;23:291\u2013304.","journal-title":"J Sex Marital Ther"},{"key":"58_CR22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/17425247.2011.628311","volume":"8","author":"A Shahiwala","year":"2011","unstructured":"Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Exp Opin Drug Deliv. 2011;8:1521\u20139.","journal-title":"Exp Opin Drug Deliv"},{"key":"58_CR23","first-page":"3231","volume":"5","author":"P Shirinbayan","year":"2010","unstructured":"Shirinbayan P, Rafiey H, Roshan AV, Narenjiiha H, Farhoudian A. Predictors of retention in methadone therapy: a prospective multicenter study. Sci Res Essays. 2010;5:3231\u20136.","journal-title":"Sci Res Essays"},{"key":"58_CR24","doi-asserted-by":"crossref","unstructured":"Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, G\u00f6lz J, Kraus MR, Tretter F, Sch\u00e4fer M, Siegert J, Scherbaum N, Rehm J, B\u00fchringer G. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend. 2008;95:245\u201357.","DOI":"10.1016\/j.drugalcdep.2008.01.015"},{"key":"58_CR25","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.addbeh.2007.01.010","volume":"32","author":"M Schiff","year":"2007","unstructured":"Schiff M, Levit S, Moreno RC. Retention and illicit drug use among methadone patients in Israel: a gender comparison. Addict Behav. 2007;32:2108\u201319.","journal-title":"Addict Behav"},{"key":"58_CR26","unstructured":"Bet\u00e4ubungsmittelverschreibungsverordnung. http:\/\/www.gesetze-im-internet.de\/btmvv_1998\/BJNR008000998.html . accessed 11 Nov 2014."},{"key":"58_CR27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0034-1367040","volume":"15","author":"F Hessel","year":"2014","unstructured":"Hessel F, Pfeiffer-Gerschel T, Reimer J. Quality in the treatment of opioid dependent patients in substitution treatment-a discussion on the background of the PREMOS-study [article in German]. Suchttherapie. 2014;15:84\u201390.","journal-title":"Suchttherapie"},{"key":"58_CR28","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3109\/10826089209047354","volume":"27","author":"WC Spring","year":"1992","unstructured":"Spring WC, Willenbring ML, Maddux TL. Sexual dysfunction and psychological distress in methadone maintenance. Int J Addict. 1992;27:1325\u201334.","journal-title":"Int J Addict"},{"key":"58_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v24n02_08","volume":"24","author":"R Brown","year":"2005","unstructured":"Brown R, Balousek S, Mundt MS, Fleming M. Methadone maintenance and male sexual dysfunction. J Addict Dis. 2005;24:91\u2013106.","journal-title":"J Addict Dis"},{"key":"58_CR30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-2007-979596","volume":"28","author":"L Teusch","year":"1995","unstructured":"Teusch L, Scherbaum N, B\u00f6hme H, Bender S, Eschmann-Mehl G, Gastpar M. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Pharmacopsychiatry. 1995;28:84\u201392.","journal-title":"Pharmacopsychiatry"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-016-0058-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T09:11:31Z","timestamp":1498295491000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-016-0058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1186\/s40360-016-0058-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,7]]},"article-number":"15"}}